Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Copenhagen Stock Exchange  >  H. Lundbeck A/S    LUN   DK0010287234

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo H. Lundbeck A/S
Engages in the research, development, production and sale of pharmaceuticals for the treatment of brain diseases

H. Lundbeck A/S is a pharmaceutical company, which is engaged in the business of research, development, production and sale of pharmaceuticals for the treatment of brain diseases.

The company was founded by Hans Lundbeck on August 14, and is headquartered in Valby, Denmark.

Number of employees : 5 811 persons.
Sales per Businesses
20132014Delta
DKK (in Million)%DKK (in Million)%
Cipralex5,93338.9%4,64734.5% -27.67%
Ebixa2,09613.7%1,0587.9% -98.11%
Other Pharmaceuticals1,83012%1,98514.7% +7.81%
Other Revenue1,4849.7%547.004.1% -171.3%
Xenazine1,4209.3%1,69512.6% +16.22%
Azilect1,3929.1%1,49711.1% +7.01%
Onfi573.003.8%923.006.9% +37.92%
Sabril530.003.5%716.005.3% +25.98%
Treanda--212.001.6%-
Brintellix--188.001.4%-
Sales per Regions
20132014Delta
DKK (in Million)%DKK (in Million)%
Rest of Europe7,02846.1%4,99137.1% -40.81%
Rest of the World4,07526.7%4,14430.8% +1.67%
United States2,63517.3%3,75827.9% +29.88%
Other Revenue1,4849.7%547.004.1% -171.3%
Denmark36.000.2%28.000.2% -28.57%
Managers
NameAgeSinceTitle
Kåre Schultz552015President & Chief Executive Officer
Sven Håkan Björklund MD, PhD592011Chairman
Anders Götzsche492007CFO & Executive VP-Information Technology
Anders Gersel Pedersen MD, PhD652000Executive Vice President-Research & Development
Jørn Møller Mayntzhusen, MBA502002Director & Senior Manager-Supply Optimisation
Mona Elisabeth Elster541994Director
Lars Søren Rasmussen572013Independent Director
Terrie Curran472014Independent Director
Henrik Sindal Jensen, PhD472004Director
Lene Skole-Sørensen572015Deputy Chairman
Shareholders
NameEquities%
Lundbeck Foundation 137,351,918 69.6%
Wellington Management Co. LLP 9,866,717 5.00%
OppenheimerFunds, Inc. 3,623,693 1.84%
TIAA-CREF Investment Management LLC 3,486,898 1.77%
Teachers Advisors, Inc. 3,153,027 1.60%
Norges Bank Investment Management 2,669,756 1.35%
Templeton Global Advisors Ltd. 1,748,890 0.89%
M&G Investment Management Ltd. 1,095,876 0.56%
The Vanguard Group, Inc. 1,059,199 0.54%
Franklin Templeton Investment Management Ltd. 1,002,440 0.51%
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Pharmaceuticals - NEC
Advertisement
Sector Pharmaceuticals
Growth (Revenue) Profitability
JOHNSON & JOHNSON
ROCHE HOLDING LTD..
NOVARTIS AG
PFIZER INC.
MERCK & CO., INC.
ALLERGAN PLC
SANOFI
NOVO NORDISK A/S
GLAXOSMITHKLINE P..
BRISTOL-MYERS SQU..
BAYER AG
ELI LILLY AND CO
ASTRAZENECA PLC
TEVA PHARMACEUTIC..
ABBOTT LABORATORI..
TAKEDA PHARMACEUT..
VALEANT PHARMACEU..
SHIRE PLC
ASTELLAS PHARMA I..
MYLAN NV
Sector Pharmaceuticals
H. Lundbeck A/S : Connections
Danish Society of Medical Oncology
Coloplast Danmark A/S
Fonden Lundbeck International Neuroscience Foundation
Rosborg Møbler A/S
Confederation of Danish Industry
Lundbeck Pharma A/S
Atos Medical AB
Danish Society of Internal Medicine
Lundbeckfond Invest A/S
MT Højgaard A/S
LEGO A/S
The British Chambers of Commerce
Lundbeck Cognitive Therapeutics A/S
DONG Energy A/S
European Society for Medical Oncology
American Chamber of Commerce Executives, Inc.
American Society of Clinical Oncology
Tryg Forsikring A/S
International Association for the Study of Lung Cancer
Coloplast Ejendomme A/S
Company contact information
H. Lundbeck A/S
Ottiliavej 9
Valby, Capital Region 2500

Phone : +45.36.30.13.11
Fax : +45.36.30.19.40
Web : www.lundbeck.com
© 2016 People , Fundamentals and Ownership